(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
H.-J. Senn Adjuvant Chemotherapy (ACT) of breast cancer has now emerged as one of the controversial su):>jects in clinical and also experimental oncology. Driven by growing frustration about stagnating cure rates in breast cancer [1,4] and stimulated by elegant demonstration of highly curative effects of adjuvant systemic therapy in animal models [6, 11] and in several childhood neoplasias [15], researchers introduced ACT to the primary treatment of breast cancer with great hope some 15 years ago. After a first wave of isolated "historic" trials with generally limited but in one case remarkable success [5, 9], a second generation of ACT studies was initiated by NSABP investigators and oncology centers in Europe [2, 6, 13]. These trials were well conducted statistically and diagnostically, and all in the early 1970s included a surgical control arm. Early and intermediate beneficial effects on relapse-free survival (RFS) after 2-3 years median observation time then prompted a whole series of ACT studies in breast cancer. These "third-gener ation" studies usually regarded some positive influence of ACT as a given fact, dropping surgical control regimens and comparing different ACT regimens, hopefully in a prospective, randomized way 1984 Fig. 1. The mushrooming of adjuvant studies in breast cancer XII Introduction [reviews in 3, 14]. The "mushrooming" of ACT studies in breast cancer during the last 10 and especially 5 years is demonstrated in Fig. 1, and it gets really cumbersome even for the insider to keep on top of the multitude of sometimes conflicting data.
Contents:
Scientific Basis of Adjuvant Chemotherapy in Breast Cancer.- The Preclinical Scientific Basis for Adjuvant Chemotherapy in Breast Cancer.- The Clinical-Scientific Basis of Adjuvant Chemotherapy in Breast Cancer.- Molecular and Cellular Mechanisms Underlying Ineffective Cancer Chemotherapy.- Impact of Early Detection of Breast Cancer on Adjuvant Chemotherapy.- Contribution of Prognostic Factors to Adjuvant Chemotherapy in Breast Cancer.- Review: Scientific Basis of Adjuvant Chemotherapy in Breast Cancer.- Clinical Results I: Experience of Randomized Trials with Surgical Controls.- Scandinavian Trials with a Short Postoperative Course Versus a 12-Cycle Course.- A Brief Overview of Findings from NSABP Trials of Adjuvant Therapy.- CMF Adjuvant Programs at the Milan Cancer Institute.- A Controlled Trial of Adjuvant Chemotherapy with Melphal-an Versus Cyclophosphamide, Methotrexate, and Fluorouracil for Breast Cancer.- Adjuvant Chemoimmunotherapy with LMF + BCG in Node-Negative and Node-Positive Breast Cancer: 8 Year Results.- Ludwig Breast Cancer Trial LBCS III: Chemo-and Endocrine Adjuvant Treatment in Postmenopausal Patients.- Postmenopausal Node-Positive Comparison of Observation with CMFP and CMFP + Tamoxifen Adjuvant Therapy An Eastern Cooperative Oncology Group Trial.- Adjuvant Systemic Therapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group's Trials of Cyclophosphamide or CMF in Premenopausal and Tamoxifen in Postmenopausal Patients.- Clinical Results II: Experience of Non-Randomized Trials with Historical or Mached Surgical Controls.- FAC + BCG as Adjuvant Therapy in Breast Cancer: An 8-Year Update.- Current Results of the University of Arizona Adjuvant Breast Cancer Trials (1974-1984).- Significance of Drug Dose, Timing and Radiotherapy in Adjuvant Therapy of Breast Cancer.- The Use of a Natural History Data Base to Compare Outcome Among Several Trials of Adjuvant Chemotherapy for Stage II Breast Cancer.- Clinical Results III: Experience of Randomized Trials Without Surgical Controls.- Adjuvant Systemic Therapy in Postoperative Node-Positive Patients with Breast Carcinoma: The CALGB Trial and the ECOG Premenopausal Trial.- Adjuvant Therapy of Breast Cancer: A Southwest Oncology Group Experience.- Short- or Long-term Chemotherapy for Node-Positive Breast Cancer: LMF 6 Versus 18 Cycles. SAKK Study 27/26.- Adjuvant Programs for Postmenopausal Women with Node-Positive Breast Cancer: Preliminary Analysis of 5-Year Results.- Review: Experience of Randomized Trials Without Surgical Controls.- Remaining Problems of Adjuvant Chemotherapy in Breast Cancer.- Second Malignant Neoplasms in Operable Carcinoma of the Breast.- Tamoxifen and Combination Chemotherapy as Adjuvant Treatment in Postmenopausal Women with Breast Cancer.- Ludwig Breast Cancer Trials LBCS III and IV: Adjuvant Endocrine Treatment in Postmenopausal Patients.- Problems of Combined Adjuvant Radiochemotherapy.- The Present Dilemma of Adjuvant Chemotherapy: Acceptance and Risks Versus Benefits.- Are Current Worldwide Studies Going to Answer the Important Questions Remaining in Adjuvant Chemotherapy of Breast Cancer?.- Closing Remarks and Outlook.- Closing Remarks and Outlook.
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag Berlin and Heidelberg GmbH & Co. K)
Publication date: December, 2011
Pages: 264
Weight: 462g
Availability: Not available (reason unspecified)
Subcategories: General, Obstetrics and Gynaecology, Oncology, Pharmacology
From the same series
Friedhelm Raue
Thomas Ried
Christian Wittekind
Florian Otto
Markus W. Buchler
C. Stroszczynski
Manfred Dietel
H.-J. Senn
Otmar Schober
Jean-Nicolas Vauthey
Elmar Detering
Richard P. Baum
G. Mathe
R. Gross
Florian Otto
Uwe M. Martens
Michail Ignatiadis
Georges Mathe
M. S. Griem
Jack Cuzick
Michael Gnant
Ute Goerling
Hans-Jorg Senn
Werner H. Kirsten
F.A. Langley
Kuan-Teh Jeang
Janusz Jankowski
J. Bernard
Thomas Moehler
Andrea Tannapfel
S.K. Carter
R. S. Nelson
Kerry S. Courneya
Rolf D. Issels
Hans-Jorg Senn
Florian Otto
W. Fischbach
Umberto Veronesi
Otmar Schober
Paul M. Schneider
Hans-Jorg Senn
Wolfgang Tilgen
Jean-Nicolas Vauthey
Richard P. Baum
J. L. Hayward
W. H. Kirsten
Henry T. Lynch
Georges Mathe
G. T. Pack
Leon Goldman
Charles G. Moertel
R.G. Freeman
L. Manuila
Agnes Glaus
Rudiger Liersch
Richard Schindler
Uwe M. Martens
W.A. Fuchs
Michail Ignatiadis
Edward S. Meek
P. Roy-Burman
Merle Mizell
Jean Lindenmann
Pavel Koldovsky
Enrico Anglesio
Georges Mathe
Hans-Jorg Senn
James H. Goldie
Donald Metcalf
Siegfried Seeber
Israel Penn
B. Sokoloff
Manfred Schwab
E. Grundmann
H.-D. Pape
Robert S. Nelson
G. Mathe
J. Lange
G. Bonadonna
J. Szymendera
H. B. Marsden
K. E. Stanley
E. Grundmann
C. Bohuon
Pierre Denoix
A. C. Templeton
Ekkehard Grundmann
Michael Wannenmacher
Ivan Damjanov
Wolf-Dieter Ludwig
Friedhelm Raue
M. L. Jacobs
H.K. Muller-Hermelink
Rita Engenhart-Cabillic
E. Grundmann
Peter M Schlag
E. Grundmann
Ekkehard Grundmann
G. Mathe
Donald Metcalf
S. Brunner
F. F. Holmes
G. Mathe
G. Mathe
Pierre Band
Stephen C. Schimpff
K. Schwemmle
Michael Gnant
K. Hoffken
Friedhelm Raue
H. R. Scheurlen
Aron Goldhirsch
H. Acker
Hans-Jorg Senn
F. G. J. Hayhoe
William Duncan
E. Thiel
Hans-Jorg Senn
K. Musshoff
Hans-Jorg Senn
A. Rossi-Fanelli
Peo C. Koller
Volker Diehl
K. Hoffken
H.-J. Senn
Bruce S. Schoenberg
G. St. Arneault
S.K. Carter
B. Henningsen
J. Hekmatpanah
G. Mathe
E. Grundmann
G. Mathe
Sam Brunner
Hans-Jorg Senn
V. Hofmann
Michael Wannenmacher
G. Wagner
Hans-Jorg Senn
Rudolf Pichlmayr
Frank M. Torti
Michael Wannenmacher
William Duncan
G. Mathe
M. Bamberg
H.-P. Lohrmann
E. Grundmann
Niels Neymark
Peter M Schlag
P. Koldovsky
G. Nass
W. Duncan
Ekkehard Grundmann
Richard P. Gallagher
Hans-Jorg Senn
W. Duncan
W. Duncan
S.K. Carter
Michael Molls
Sam Brunner
Peter Boyle
Maurizio Ponz de Leon
U. Reinhold
Gunter Burg
K. Hoffken
H.-J. Senn
F.W. Schildberg
Beat Thurlimann
Janusz Jankowski
Thomas Moehler
Andrea Tannapfel
Kerry S. Courneya
H.-J. Senn
Per-Ulf Tunn
Andreas von Deimling
Antonella Surbone
Ursula Kapp
Hans-Jorg Senn
Santiago Gonzalez-Moreno
Hanno Riess
Paul M. Schneider
Uwe M. Martens
Rudiger Liersch
Renzo Brun del Re
Andreas von Deimling
Ursula Kapp
Per-Ulf Tunn
Hanno Riess
Antonella Surbone
Manfred Dietel
Santiago Gonzalez-Moreno
Louis Denis
H.-J. Senn
C. Stroszczynski